Business Consulting · Launch & Brand Strategy
Launch & Post-LaunchÂ
Diagnostic Intelligence
One integrated diagnostic. Four lenses. One story. We help pharma commercial teams turn fragmented sales, field, access, and account signals into a defensible answer on whether a launch is on track — and where to focus next.
AI doesn't know your market.
It doesn't know why Italy is behind and Spain is ahead.Â
We do.
Trusted by commercial teams launching in specialty therapy areas across the EU.
01 · The moment this is built for
Every launch reaches the point where
leadership asks the hard question.
The product is live. The data exists — sales, field, access, invoice, account signals, owned by a dozen different teams. But nobody can give a clean answer on whether the launch is on track, or what to do next. That's the moment this diagnostic is built for.
01
Fragmented
Today
Sales, field, access, invoice, and account data
sit in different systems, owned by different
teams. Every QBR is a debate about whose numbers are right.
​
​
02
phamax Brings
Connected & AI-ready
Domain experts harmonise, govern, and
reconcile the foundation — pharma-fluent
from day one, built to be trusted before it
reaches a leadership screen.
​
​
03
Outcome
One defensible diagnostic
Leadership walks in with one agreed answer
on where momentum is concentrated, what's holding it back, and where to invest next.
​
​
Lens 04
Patient coverage
Knowing where patients are —
and whether the field has actually reached them — is the difference between a coverage strategy
and a guess.
Competitive position
The question is rarely whether
a competitor has an advantage. It's where, by how much, and whether
the gap is closing or widening. External market data sits alongside internal sales.
Lens 02
Sales attainment
National numbers flatten the story.
A strong quarter in one region can mask underperformance in three others. The diagnostic breaks the market down geographically —Â
a map, not a national average.
Lens 01
Commercial performance
Before every leadership meeting, the team needs to answer one question quickly and consistently: is the launch on track? The diagnostic puts the full commercial picture in one view, from one reconciled source.
This is not a dashboard project and not a list of decision packs. It is a single diagnostic that examines a launch through four lenses commercial leadership already cares about — each designed to answer a question the team is already asking.
One integrated diagnostic.Â
Four lenses. One story.Â
02 · What we deliver
Same data the client already has. New foundation. New diagnostic. New conversation with leadership.
03 · How we get there
Connect. Examine. Decide.
A three-step approach that turns fragmented commercial signals into defensible decisions for the next phase of growth.
01
Connect
Build the foundation
Fragmented commercial, market, sales and field inputs harmonised into one decision-ready intelligence layer — pharma-fluent and governed.
​
​
02
Examine
Apply the diagnostic
The launch examined through four targeted diagnostic lenses, each designed to answer a specific question leadership is already asking.
​
​
03
Decide
Recommend the next move
Performance signals translated into territory-level recommendations — defensible decisions for the next phase of growth.
​
​
04 · Proof, from the field
Unlocking full market potential throughÂ
post-launch signals.
Rare Disease · Oncology · Germany
3
Outcome
Pre-meeting reconciliation disappeared. Leadership reviewed performance from one shared foundation — and the conversation shifted from "whose numbers are right?" to "what should we do next?" Regional decision-making replaced national averages. Field deployment was tied to patient opportunity, not assumption.
2
Approach
phamax built a decision-ready intelligence layer — connecting commercial, market, sales, and field inputs into one governed foundation. A diagnostic framework was then applied across four lenses: commercial performance, sales attainment, competitive position, and patient opportunity & field coverage.
1
Challenge
A global oncology company was over a year into a German rare disease launch, competing against an established incumbent. Performance data existed in volume but sat across teams, formats, and reporting layers. One question defined the next planning cycle:Â where was the launch gaining traction, and where did resources need to be redirected?
200+
Brick-level regions analysed across Germany
4
Diagnostic lenses across performance, competition and field priorities
1
Decision-ready foundation, ready for AI-enabled analytics next
04
Leadership review or brand planning is coming up,
and the team needs
a defensible narrative.
03
Sales, field, access, and account data sit in separate systems.
02
Uptake is uneven across markets, regions, or accounts.
01
A specialty product has launched in the last 6–24 months.
